Approval

Five things for pharma marketers to know: Friday, September 19

Five things for pharma marketers to know: Friday, September 19

By

Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.

Merck scores first US PD-1 approval

Merck scores first US PD-1 approval

By By

The FDA approved the drug previously known as pembrolizumab, now known as Keytruda, for patients with unresectable or metastatic melanoma who have taken Bristol-Myers Squibb's Yervoy (ipilimumab).

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

By

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for pharma marketers to know: Monday, August 25

Five things for pharma marketers to know: Monday, August 25

By

Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

By

The FDA has approved Arnuity Ellipta for asthma.

Biogen twice-monthly MS drug approved

Biogen twice-monthly MS drug approved

By

Plegridy is the only pegylated beta-interferon drug approved for relapsing multiple sclerosis.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

MannKind's Afrezza approved

MannKind's Afrezza approved

By

The FDA approved the inhaled insulin last week.

FDA OKs Merck clot drug

Zontivity (vorapaxar) was approved for patients who have already suffered a heart attack or have arterial blockages in the legs.

Latest Breakthrough nod goes to Novartis

The FDA announced Tuesday its approval of lung cancer drug Zykadia for patients with metastatic ALK-positive non-small cell lung cancer.

J&J cancer med adds indication, lower dose

J&J cancer med adds indication, lower dose

By

The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.

JAMA studies look at FDA rejections and approvals

JAMA studies look at FDA rejections and approvals

By

Two JAMA articles and an editorial give a rundown of what the FDA leaves unsaid in its approvals process and how general housekeeping items can get drugs rejected.

UK seeks own Breakthrough Therapy program

Reports are that the UK wants an expedited process that will mirror the FDA's.

EMA approves ViiV's Tivicay

The GlaxoSmithKline-Pfizer-Shionogi joint venture scored an FDA approval in August.

Oral form of Remodulin approved

The FDA approved Orenitram (treprostinil), after rejecting it twice before.

FDA's 2013 so far: 26 approvals

FDA's 2013 so far: 26 approvals

By

The FDA's Center for Drug Evaluation and Research released a preliminary year-in-review report that says the agency has cleared 26 new molecular entities this year.

J&J HCV drug OK'd; educational push planned

J&J HCV drug OK'd; educational push planned

By

Janssen's hepatitis C drug Olysio (simeprevir) offers modest benefit over standard of care, but resistance in a subgroup of patients could hinder broader uptake.

Roche lands EU Kadcyla approval, ducks EMA criticism

The drugmaker's green light was paired with the EMA's decision that several thousand unreported AEs were no big deal.

GSK's Breo approved in Europe, COPD market may be underestimated

GSK's Breo approved in Europe, COPD market may be underestimated

By

Known as Breo Ellipta in the US, GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD. The overall market is expected to continue to grow, but an NIH study indicates more patient conversations need to happen.

FDA approves Imbruvica (ibrutinib) for MCL

FDA approves Imbruvica (ibrutinib) for MCL

By

The company also has breakthrough therapy designations for CLL and Waldenstrom's macroglobulinemia.

Researchers say follow money, not FDA approvals

Researchers say follow money, not FDA approvals

By

A report says this year's approvals could be worth more than last year's, even though the number of approvals will be fewer.

Gazyva's nod gives Roche a Rituxan successor

Gazyva's nod gives Roche a Rituxan successor

By

The regulator approved the CLL medication Friday, giving the drugmaker time to create a marketing transition before Rituxan goes generic. The approval marks another milestone: the first drug approved with a Breakthrough Designation label, a tag that is now coming under scrutiny.

Novo hemophila drug approved

The FDA approved Novoeight, for hemophilia A patients.

FDA reviews continue for now

Approvals and reviews continue—for now—despite government shutdown.

Lundbeck scores FDA approval, reorganizes

Lundbeck scores FDA approval, reorganizes

By

The FDA approved the drug maker's depression drug Brintellix, one day after the Danish company announced a reorg that includes shifting 180 to 200 jobs.

FDA okays Perjeta for first-line breast cancer treatment

FDA okays Perjeta for first-line breast cancer treatment

By

The second-line drug sped from Priority Review status for the first-line indication to approval in just over two months.

Business briefs: AbbVie, FDA, and health spending projections

AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011

Business briefs: Biogen, Celgene, J&J, plus Obamacare TV push

Biogen extend Isis relationship for six years and $100M; HHS readies healthcare reform TV push; Medivir ends hep. B clinical trial; FDA approves Celgene cancer drug; Baxter seeks Enbrel biosimilar

GSK clears another flu vaccine, but patients may not be buying

GSK clears another flu vaccine, but patients may not be buying

By

The FDA approved GlaxoSmithKline's second quadrivalent flu vaccine, but a CVS study indicates that consumers are big fans of the vaccination, as long as they aren't the ones rolling up their sleeves.

New daily HIV med could put Atripla on the defensive

New daily HIV med could put Atripla on the defensive

By

The GSK-Pfizer-Shionogi daily HIV medication gets the regulatory all-clear. The approval could put BMS/Gilead's best-selling daily med Atripla on the defensive.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters